LGALS9 and small cell lung carcinoma: The survival analysis indicated that patients with extensive SCLC with higher Gal-9 expression level showed better overall survival (OS) than patients with lower Gal-9 expression (16.0 months, 95% CI: 7.4–24.6 vs 7.0 months, 95% CI: 2.1–11.9; p=0.122; online supplemental figure S3B).